These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 14713749)
1. Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression. Makridakis NM; Reichardt JK J Urol; 2004 Feb; 171(2 Pt 2):S25-8; discussion S28-9. PubMed ID: 14713749 [TBL] [Abstract][Full Text] [Related]
2. Androgen metabolic genes in prostate cancer predisposition and progression. Makridakis NM; Buchanan G; Tilley W; Reichardt JK Front Biosci; 2005 Sep; 10():2892-903. PubMed ID: 15970543 [TBL] [Abstract][Full Text] [Related]
3. GEN GEN: the genomic genetic analysis of androgen-metabolic genes and prostate cancer as a paradigm for the dissection of complex phenotypes. Reichardt JK Front Biosci; 1999 Jul; 4():D596-600. PubMed ID: 10417059 [TBL] [Abstract][Full Text] [Related]
4. [Polymorphisms of hormone-related genes and prostate cancer risk in Japan]. Watanabe M; Hirokawa Y; Shiraishi T Nihon Rinsho; 2005 Feb; 63(2):219-24. PubMed ID: 15714969 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of human androgens and prostatic diseases. Novelli G; Margiotti K; Sangiuolo F; Reichardt JK Pharmacogenomics; 2001 Feb; 2(1):65-72. PubMed ID: 11258198 [TBL] [Abstract][Full Text] [Related]
6. Molecular epidemiology of hormone-metabolic loci in prostate cancer. Makridakis NM; Reichardt JK Epidemiol Rev; 2001; 23(1):24-9. PubMed ID: 11588850 [No Abstract] [Full Text] [Related]
7. Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Ntais C; Polycarpou A; Tsatsoulis A Eur J Endocrinol; 2003 Dec; 149(6):469-77. PubMed ID: 14640986 [TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of human androgens and prostate cancer--an update. Novelli G; Margiotti K; Chiocca AM; Spera E; Micali F; Reichardt JK Pharmacogenomics; 2004 Apr; 5(3):283-94. PubMed ID: 15102543 [TBL] [Abstract][Full Text] [Related]
9. Androgens and the molecular epidemiology of prostate cancer. Chu LW; Reichardt JK; Hsing AW Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):261-70. PubMed ID: 18438175 [TBL] [Abstract][Full Text] [Related]
10. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer. Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450 [TBL] [Abstract][Full Text] [Related]
11. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867 [TBL] [Abstract][Full Text] [Related]
12. Genetic variation: effect on prostate cancer. Sissung TM; Price DK; Del Re M; Ley AM; Giovannetti E; Figg WD; Danesi R Biochim Biophys Acta; 2014 Dec; 1846(2):446-56. PubMed ID: 25199985 [TBL] [Abstract][Full Text] [Related]
13. [Molecular epidemiology and cancer prevention]. Kamoto T; Ogawa O; Habuchi T; Kato T Hinyokika Kiyo; 2001 Nov; 47(11):833-6. PubMed ID: 11771181 [TBL] [Abstract][Full Text] [Related]
14. Profiling genetic variation along the androgen biosynthesis and metabolism pathways implicates several single nucleotide polymorphisms and their combinations as prostate cancer risk factors. Mononen N; Seppälä EH; Duggal P; Autio V; Ikonen T; Ellonen P; Saharinen J; Saarela J; Vihinen M; Tammela TL; Kallioniemi O; Bailey-Wilson JE; Schleutker J Cancer Res; 2006 Jan; 66(2):743-7. PubMed ID: 16424004 [TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. Mononen N; Schleutker J J Urol; 2009 Apr; 181(4):1541-9. PubMed ID: 19230916 [TBL] [Abstract][Full Text] [Related]
16. Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment. Henríquez-Hernández LA; Valenciano A; Foro-Arnalot P; Álvarez-Cubero MJ; Cozar JM; Suárez-Novo JF; Castells-Esteve M; Fernández-Gonzalo P; De-Paula-Carranza B; Ferrer M; Guedea F; Sancho-Pardo G; Craven-Bartle J; Ortiz-Gordillo MJ; Cabrera-Roldán P; Herrera-Ramos E; Rodríguez-Gallego C; Lara PC J Genet; 2015 Jun; 94(2):335-41. PubMed ID: 26174685 [No Abstract] [Full Text] [Related]
17. Polymorphism of the SRD5A2 gene and the risk of prostate cancer. Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105 [TBL] [Abstract][Full Text] [Related]
18. Inherited variation in hormone-regulating genes and prostate cancer survival. Lindström S; Adami HO; Bälter KA; Xu J; Zheng SL; Stattin P; Grönberg H; Wiklund F Clin Cancer Res; 2007 Sep; 13(17):5156-61. PubMed ID: 17785571 [TBL] [Abstract][Full Text] [Related]
19. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men. Allen NE; Reichardt JK; Nguyen H; Key TJ Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006 [TBL] [Abstract][Full Text] [Related]